NEW YORK (GenomeWeb News) – Orchid Cellmark plans to shut down its paternity testing operations in East Lansing, Mich., and move them to its facilities in Dayton, Ohio, the company said today.

The DNA testing firm plans to bring all of its US paternity operations "under one roof" in an effort to increase efficiency, Orchid CEO Thomas Bologna said in a statement today. The Dayton facility already houses some paternity testing services, and the company's call center and customer operations are based in Dayton as well, Bologna said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.